

Abbreviations

ABS	Antibiotic stewardship
AGP	Antimicrobial growth promoters
AMR	Antimicrobial resistance
AMS	Antimicrobial stewardship
AMU	Antimicrobial use
ARB	Antibiotic-resistant bacteria
ARC	Antibiotic Resistance Coalition
ASP	Antibiotic stewardship programme
BARDA	Biomedical Advanced Research and Development Authority
BSI	Bloodstream infection
CARB-X	Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator
CCCAS	Clinician Champions in Comprehensive Antibiotic Stewardship
CDC	Centers for Disease Control
CEWG	Consultative Expert Working Group
CRE	Carbapenem-resistant Enterobacteriaceae
CRP	C-reactive Protein
CSE	Centre for Science and Environment
CSF	Cerebrospinal fluid
DALY	Disability-adjusted life-year
DDD	Defined Daily Dose
DG-RTD	Directorate-General for Research and Innovation
DP	Delayed prescribing
DRG	Diagnosis-related group
EARSS	European Antibiotic Resistance Surveillance System
EARS-NET	European Antibiotic Resistance Surveillance Network
EC	Environmental cleaning
ECDC	European Centre for Disease Prevention and Control

EDCTP	European and Developing Countries Clinical Trial Partnership
EEA	European Economic Area
EFPIA	European Federation of Pharmaceutical Industries and Associations
EFSA	European Food Safety Authority
EIB	European Investment Bank
EMA	European Medicines Agency
EPOC	Effective Practice and Organisation of Care
ESBL	Extended spectrum beta-lactamase
ETEC	Enterotoxigenic <i>Escherichia coli</i>
EU	European Union
FAO	Food and Agricultural Organization
FDA	Food and Drug Administration
G3REC	Third-generation cephalosporin
GAMRIF	Global Antimicrobial Resistance Innovation Fund
GARDP	Global Antibiotic Research and Development Partnership
GBS	Group B Streptococcus
GDP	Gross Domestic Product
GLASS	Global Antimicrobial Resistance Surveillance System
GP	General practitioner
GRACE INTRO	Genomics to combat Resistance against Antibiotics for Community-acquired LRTI in Europe/ INternet Training for Reducing antibiOtic use
HAI	Health care-associated infection/hospital-acquired infection
HIV	Human immunodeficiency virus
HTA	Health technology assessment
ICU	Intensive-care units
ID	Infectious diseases
IMI	Innovative Medicine's Initiative
IPC	Infection prevention and control
JPIAMR	Joint Programming Initiative on Antimicrobial Resistance
KISS	Krankenhaus-Infektions-Surveillance-System
LMIC	Low- and middle-income country
LOS	Length of stay

LPAD	Limited Population Antibacterial Drug
mAb	Monoclonal antibody
MER	Market entry rewards
MRSA	Methicillin-resistant <i>Staphylococcus aureus</i>
MSF	Médecins sans Frontières
NHS	National Health Service
NIAID	National Institute of Allergy and Infectious Diseases
NIH	National Institutes for Health
NIHR	National Institute for Health Research
NRDC	Natural Resources Defense Council
OECD	Organisation for Economic Co-operation and Development
OIE	World Organisation for Animal Health
PCR	Polymerase chain reaction
PDP	Product development partnerships
PIRG	Public Interest Research Group
PMDA	Pharmaceuticals and Medical Devices Agency
POC	Point of care
POCT	Point-of-care tests
PPL	Priority Pathogens List
PPS	Point prevalence surveys
PRV	Priority review vouchers
QALY	Quality-adjusted life-years
QIDP	Qualified Infectious Diseases Products
R&D	Research and development
RCDC	Research, condition, and disease categories
RCT	Randomized controlled trial
RSV	Respiratory syncytial virus
RTI	Respiratory tract infections
SDM	Shared decision-making
SME	Small and medium enterprises
STEC	Shiga toxin-producing <i>Escherichia coli</i>
SWAB	Working Party on Antibiotic Policy
TATFAR	Transatlantic Task Force on Antimicrobial Resistance
TIPR	Transferable intellectual property rights
TPP	Target Product Profile
UNICEF	United Nations Children's Fund
UI	uncertainty interval
UPEC	Uropathogenic <i>Escherichia coli</i>

USDA	US Department of Agriculture
UTI	Urinary tract infections
VRE	Vancomycin-resistant enterococci
VTEC	Verocytotoxin-producing <i>Escherichia coli</i>
WHO	World Health Organization
WTO	World Trade Organization